Inari Medical (NARI) Investor Presentation - Slideshow

Company Overview - Inari Medical offers purpose-built solutions and differentiated devices for venous thrombectomy [9] - The company's core VTE market opportunity is $58 billion in the U S alone, with Inari penetration remaining less than 5% [9] - Inari has a robust product pipeline, launching 6 new products YTD in 2022 [9] Products and Solutions - ClotTriever system is effective on clot of all ages, with 91% complete or near complete thrombus removal for acute clots, 82% for subacute, and 84% for chronic [45] - FlowTriever is designed to extract large volumes of clot, offering a lytic-free approach [58] - FlowTriever aspiration flow rate is 8x greater than 12F catheter [62] Clinical Evidence and Studies - ClotTriever studies show 92% complete or near complete thrombus removal, 99% single session rate, 1% received lytics, 0 0% major bleeding, and 0 0% acute kidney injury [77, 78, 79] - FlowTriever studies show 1 6% acute mortality, 0 0% device related mortality, 7 0 mmHg average mPAP decrease, 1 0% major bleeding, and 0 9-day average ICU stay [81, 82] - PEERLESS is an RCT of FlowTriever vs catheter-directed thrombolytics in pulmonary embolism, enrolling up to 700 patients [83] Financial Performance - The company's Q3 2022 revenue was $96 2 million, with 4% sequential growth from Q2 2022 and 32% growth YoY from Q3 2021 [93] - Q3 YTD 2022 revenue mix was 32% CT and 68% FT [93] - Gross margin was 88 6% in Q3 2022 [93]